Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
Rapid injection forces medication into the tissue faster than it can accommodate, creating a pressurized pocket that causes pain and can push medication back out through the needle track
The safety and effectiveness of Vyvanse for the treatment of obesity have not been established. Risks of Vyvanse for weight loss As Alex Foxman, MD, internist and medical director of Achieve Health and Weight Loss, emphasizes, Vyvanse is not a safe or effective way to lose weight outside of healthcare provider-guided binge eating disorder treatment
10 Smart Ways to Manage Your Diabetes Diabetes can be challenging to manage
To view or add a comment, sign in 1,099 followers
A consultation with a provider to determine candidacy is recommended
